BRAF and melanoma: Nagore et al. showed that coexistence of TERT promoter and BRAF or NRAS mutations was associated with a 2-fold reduced rate of disease-free survival and a 5-fold reduced rate of melanoma-specific survival in patients with stage I and II melanoma26.